Last reviewed · How we verify
TheraTears Lubricating Eye Drops
At a glance
| Generic name | TheraTears Lubricating Eye Drops |
|---|---|
| Also known as | 87049747 |
| Sponsor | Koffler Vision Group |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparative Efficacy of Lipid Based Artificial Tears vs Aqueous Based Artificial Tears in Managing EDE (NA)
- Laser Acupuncture for Dry Eye Disease Due to Visual Display Terminal Use (NA)
- Hyaluronic Acid-containing Artificial Tears in Post-cataract Surgery Dry Eye Disease (PHASE4)
- Effects of Carboxymethylcellulose Artificial Tears on the Eye Microbiome (PHASE4)
- Tear Lipid Layer Thickness With Emollient Eye Drops (PHASE4)
- Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy (PHASE4)
- Post Intravitreal Injection Topical NSAID vs. Patching (PHASE4)
- Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TheraTears Lubricating Eye Drops CI brief — competitive landscape report
- TheraTears Lubricating Eye Drops updates RSS · CI watch RSS
- Koffler Vision Group portfolio CI